Activin A Predicts Left Ventricular Remodeling and Mortality in Patients with ST-Elevation Myocardial Infarction

作者：Lin Jeng Feng; Hsu Shun Yi; Teng Ming Sheng; Wu Semon; Hsieh Chien An; Jang Shih Jung; Liu Chih Jen; Huang Hsuan Li; Ko Yu Lin^*

来源：Acta Cardiologica Sinica, 2016, 32(4): 420-427.

DOI：10.6515/ACS20150415A

• Activin A
• Acute myocardial infarction
• Left ventricular remodeling

Background: Activin A levels increase in a variety of heart diseases including ST-elevation myocardial infarction (STEMI). The aim of this study is to investigate whether the level of activin A can be beneficial in predicting left ventricular remodeling, heart failure, and death in patients with ST-elevation myocardial infarction (STEMI).
Methods: We enrolled 278 patients with STEMI who had their activin A levels measured on day 2 of hospitalization. Echocardiographic studies were performed at baseline and were repeated 6 months later. Thereafter, the clinical events of these patients were followed for a maximum of 3 years, including all-cause death and readmission for heart failure.
Results: During hospitalization, higher activin A level was associated with higher triglyceride level, lower left ventricular ejection fraction (LVEF), and lower left ventricular end diastolic ventricular volume index (LVEDVI) in multivariable linear regression model. During follow-up, patients with activin A levels > 129 pg/ml had significantly lower LVEF, and higher LVEDVI at 6 months. Kaplan-Meier survival curves showed that activin A level > 129 pg/ml was a predictor of all-cause death (p = 0.022), but not a predictor of heart failure (p = 0.767).
Conclusions: Activin A level > 129 pg/ml predicts worse left ventricular remodeling and all -cause death in STEMI.

• 出版日期2016-7